Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Small Cell Lung Cancer(ALTER1202)

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Small Cell Lung Cancer(ALTER1202)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Catequentinib (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ALTER1202
  • Sponsors Chia Tai Tianqing Pharmaceutical Group

    • Most Recent Events

    • 12 Aug 2021 Results assessing cost-effectiveness analysis of anlotinib as third- or further-line of treatment in patients with relapsed advanced small cell lung cancer in China, published in the Advances in Therapy.
    • 18 May 2021 Results evaluating the efficacy and safety of anlotinib as a third-line and subsequent treatment for patients with small cell lung cancer, published in the British Journal of Cancer
    • 21 Sep 2020 Results of a comparative analysis for patients with pleural metastases/pleural effusion in a subgroup of patients, presented at the 45th European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top